Cypress Eyeing $200-400 Mil. Prosorba Sales Based On 1-2% Of RA Market
This article was originally published in The Gray Sheet
Executive Summary
Cypress Bioscience expects its Prosorba column for treatment of rheumatoid arthritis to be a $200-400 mil. product by 2003, the company said following FDA's premarket approval of the device March 16. The PMA was submitted last July.